Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.
- DOI
- 10.1136/jitc-2025-014325
- Published
- 2026 May 8
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2025-014325,
title = {Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.},
author = {Naing A and Spreafico A and Barve M and Patnaik A and Ianopoulos X and Drean P and Skartved NJ and Hemon A and Kantari-Mimoun C and He P and Askoxylakis V and Lakhani N},
year = {2026},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2025-014325},
url = {https://doi.org/10.1136/jitc-2025-014325}
}RIS
TY - JOUR TI - Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. AU - Naing A AU - Spreafico A AU - Barve M AU - Patnaik A AU - Ianopoulos X AU - Drean P AU - Skartved NJ AU - Hemon A AU - Kantari-Mimoun C AU - He P AU - Askoxylakis V AU - Lakhani N PY - 2026 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2025-014325 UR - https://doi.org/10.1136/jitc-2025-014325 ER -
APA
A, N., A, S., M, B., A, P., X, I., P, D., NJ, S., A, H., C, K., P, H., V, A., & N, L. (2026). Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-014325
Source records
- pubmed · retrieved 2026-09-25T11:47:10.173Z